<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440112</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00360361-A</org_study_id>
    <secondary_id>R01NS099535</secondary_id>
    <nct_id>NCT03440112</nct_id>
  </id_info>
  <brief_title>Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm</brief_title>
  <acronym>GABA-A</acronym>
  <official_title>Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicolaas Bohnen, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The arm of this study evaluates possible GABA-A receptor target engagement effects of the
      FDA-approved medication, transdermal flumazenil (added 4/2020, replaced clarithromycin), in
      the setting of Parkinson's disease. Half of the subjects will receive transdermal flumazenil
      for 7-10 days, and half will receive a placebo. [11C]Flumazenil GABA-A receptor PET imaging
      will be used to assess target engagement effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study focuses on neurochemical changes in the brain that occur in Parkinson's disease.
      In particular we will be looking a neurotransmitter called GABA. In some Parkinson's disease
      patients we see too much GABA activity in the brain. This target engagement study examines
      the target engagement effect of GABA-A receptor modulation by transdermal flumazenil
      (previously clarithromycin). [11C]-flumazenil Positron Emission Tomography (PET) imaging
      results will be used to assess for possible GABA-A receptor target engagement effects of
      transdermal flumazenil (previously clarithromycin).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participant, Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in [11-Carbon]-flumazenil ([11C]FMZ) PET Binding</measure>
    <time_frame>7-10 days</time_frame>
    <description>We will use brain PET imaging to assess quantitative changes in GABA-A receptors before and after the administration of clarithromycin in Parkinson disease subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quantitative biomechanics</measure>
    <time_frame>7-10 days</time_frame>
    <description>We will use the PIGD-UPDRS motor scale to assess axial motor functions before and after 7 days of clarithromycin and correlate this with the [11C]FMZ PET binding study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Clarithromycin (Not used anymore as of 4/2020)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Not used anymore as of 4/2020)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal flumazenil (added 4/2020)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream (added 4/2020)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin (Not used as of 4/2020)</intervention_name>
    <description>Clarithromycin (generic) capsule 250mg each</description>
    <arm_group_label>Clarithromycin (Not used anymore as of 4/2020)</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Not used as of 4/2020)</intervention_name>
    <description>Lactose in a gel capsule</description>
    <arm_group_label>Placebo (Not used anymore as of 4/2020)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal flumazenil (Added 4/2020)</intervention_name>
    <description>Transdermal flumazenil 24mg/mL</description>
    <arm_group_label>Transdermal flumazenil (added 4/2020)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Added 4/2020)</intervention_name>
    <description>Transdermal placebo</description>
    <arm_group_label>Placebo cream (added 4/2020)</arm_group_label>
    <other_name>Placebo cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parkinson's disease (PD): PD diagnosis will follow the UK Parkinson's Disease Society
             Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD.

          2. Hoehn and Yahr stages 2-4

          3. Absence of dementia confirmed by cognitive testing.

          4. Abnormal 11C-Dihydrotetrabenazine ([11c]-DTBZ) PET study to demonstrate nigrostriatal
             dopaminergic denervation

        Exclusion Criteria:

          1. PD with Dementia (PDD) or dementia with Lewy bodies (DLB).

          2. Other disorders which may resemble PD, such as vascu¬lar dementia, normal pressure
             hydrocephalus, multiple system atrophy, corticobasal ganglionic dege¬neration, or
             toxic causes of parkinsonism. Prototypical cases have distincti¬ve clinical profiles,
             like early and severe dysautonomia or appendicular apraxia, which may differentiate
             them from idiopathic PD. The use of the UKPDSBRC clinical diagnostic criteria for PD
             will mitigate the inclusion of subjects with atypical parkinsonism.

          3. Subjects currently on benzodiazepine, GABAB-ergic medications (baclofen, tizanidine),
             modafinil, neuroleptic, anticholinergic (trihexyphenidyl, benztropine), or
             cholinesterase inhibitor drugs.

          4. Evidence of a mass lesion on structural brain imaging (MRI).

          5. Participants in whom MRI is contraindicated including, but not limited to, those with
             a pacemaker, presence of metallic fragments near the eyes or spinal cord, chest, or
             cochlear implant.

          6. Severe claustrophobia precluding MR or PET imaging.

          7. Subjects limited by participation in research procedures involving ionizing radiation.

          8. Pregnancy (urine or serum pregnancy test within 48 hours of each PET session) or
             breastfeeding.

          9. History of seizures

         10. Significant anxiety or history of panic disorder.

         11. History of recent suicide attempt or overdose of tricyclic antidepressants or other
             medications.

         12. History of transient ischemic attack (TIA) or stroke within the last year.

         13. History of systemic lupus erythematosis.

         14. Abnormal liver enzymes (AST or ALT) &gt; 3 times upper limit of normal.

         15. History of atrial fibrillation.

         16. History of retinal branch artery occlusion.

         17. Active dermatitis inner forearms.

         18. Any other medical history determined by investigators to preclude safe participation.

        Additional Exclusion Criteria for Flumazenil sub-studies:

          1. Allergy to flumazenil

          2. Significant liver disease

          3. History of alcohol or other substance abuse within past two years.

          4. Subjects currently taking benzodiazepines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas I Bohnen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Minderovic, BS</last_name>
    <phone>734-998-8400</phone>
    <email>cmindero@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyrus Sarosh, MS</last_name>
    <phone>734-998-8400</phone>
    <email>csarosh@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muller</last_name>
      <phone>734-998-8400</phone>
      <email>mtmuller@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarosh</last_name>
      <phone>734-998-8400</phone>
      <email>csarosh@umich.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Nicolaas Bohnen, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Radiology and Neurology</investigator_title>
  </responsible_party>
  <keyword>Gait</keyword>
  <keyword>Balance</keyword>
  <keyword>GABA</keyword>
  <keyword>Transdermal flumazenil (previously Clarithromycin changed 4/2020)</keyword>
  <keyword>PET Imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Mobility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

